Enke Grabhorn

Dr. Enke Grabhorn


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Transplantation
Verified
Journal Article
Closed access
EGEnke Grabhorn
Enke Grabhorn
TBThomas M. C. Binder
Thomas M. C. Binder
DODenise Obrecht
Denise Obrecht
FBFlorian Brinkert
Florian Brinkert
ALAnja Lehnhardt
Anja Lehnhardt
ABAndrea Briem-Richter
Andrea Briem-Richter
Background Anti-HLA antibodies and especially donor-specific antibodies (DSA) play a significant role in graft survival after solid organ transplantation. Their impact on long-term survival in adult liver transplantation (LT) is controversial, but they may be a risk factor. The effects of DSA after pediatric LT are still unclear. Methods We performed a retrospective evaluation of DSA in sera from 43 children who had received transplants at our tertiary center. Twenty-four patients had good long-term clinical and laboratory graft function (group 1), whereas 19 LT recipients suffered from histologically confirmed and clinically relevant chronic allograft rejection (group 2); 16 of these have already undergone retransplantation due to graft dysfunction. Inclusion criteria were availability of sera before the first LT to identify preformed antibodies in case of DSA positivity after LT and long-term follow-up at our institution. Sera were analyzed for anti-HLA antibodies using Luminex single antigen beads, where a mean fluorescence intensity value of more than 1500 was considered positive. Results The prevalence of DSA was 33% for group 1 and 68% for group 2. Antibodies were predominantly HLA class II. Values of mean fluorescence intensity were comparable in both groups. Only one of the DSA+ ve patients from group 1 exhibited preformed antibodies. In conclusion, pediatric patients with chronic rejection revealed a higher rate of de novo DSA, especially of HLA-class II DSA. Further studies are necessary to confirm these data with a larger pediatric cohort.

30 January 2014 in Liver Transplantation
Verified
Journal Article
Open access
PDF file
EGEnke Grabhorn
Enke Grabhorn
KTKonstantinos Tsiakas
Konstantinos Tsiakas
UHUta Herden
Uta Herden
LFLutz Fischer
Lutz Fischer
PFPeter Freisinger
Peter Freisinger
RSRené Santer
René Santer
Deoxyguanosine kinase (DGUOK) deficiency is a well-known cause of hepatocerebral mitochondrial DNA depletion syndromes, which include a broad spectrum of clinical presentations. Affected patients often develop life-threatening liver failure, but the benefits of liver transplantation (LT) are controversial because of the frequently severe neurological involvement due to the underlying mitochondrial disease. We describe the long-term clinical course of 2 patients from our institution and provide an update on their outcomes after LT with this condition. Another 12 pediatric patients were identified through a systematic search of the literature. All 14 reported patients underwent transplantation in infancy despite mild to moderate neurological impairment in some cases. The 2 DGUOK-deficient patients from our center displayed liver failure and mild to moderate neurological involvement. At the time of this writing, they had been followed for 5 and 8 years after LT, both patients were alive, and they had only mild neurological symptoms. Three of the 12 patients identified through the literature review survived for a long time (17, 12, and 23 years); 8 died during early follow-up; and for 1 patient, no follow-up information was available. The 1-year survival rate was 64%; 36% survived for more than 5 years. The long-term survivors had good quality of life. In conclusion, although survival after LT for DGUOK deficiency is lower than survival after LT for other indications, a significant proportion of patients benefit from LT with long-term survival and a stable neurological situation despite initial neurological abnormalities. Nevertheless, a decision to carry out LT for patients with DGUOK deficiency remains difficult because neurological symptoms may occur and worsen after LT despite their absence before transplantation. Liver Transpl 20:464–472, 2014. © 2014 AASLD.

31 May 2013 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
EGEnke Grabhorn
Enke Grabhorn
DNDirk Nielsen
Dirk Nielsen
GHGeorg Hillebrand
Georg Hillebrand
FBFlorian Brinkert
Florian Brinkert
UHUta Herden
Uta Herden
RGRainer Ganschow
Rainer Ganschow

27 June 2021 in World Journal of Hepatology
Verified
Journal Article
Open access
FSFelicitas Leonie Schotters
Felicitas Leonie Schotters
JBJan Beime
Jan Beime
ABAndrea Briem-Richter
Andrea Briem-Richter
TBThomas Binder
Thomas Binder
UHUta Herden
Uta Herden
EGEnke Grabhorn
Enke Grabhorn
Impact of donor-specific antibodies on long-term graft survival with pediatric liver transplantation

5 February 2021 in Clinical Transplantation
Verified
Journal Article
Open access
PDF file
HSHanna Schröder
Hanna Schröder
NJNorman Junge
Norman Junge
UHUta Herden
Uta Herden
ADAndrea Deutschmann
Andrea Deutschmann
SWSören Alexander Weidemann
Sören Alexander Weidemann
EGEnke Grabhorn
Enke Grabhorn
Introduction: Crigler‐Najjar syndrome (CNS) is a rare inherited disorder that is characterized by high levels of non‐hemolytic, unconjugated hyperbilirubinemia leading to brain damage and even death. Liver transplantation (LT) can correct the metabolic defect, but there are little data regarding LT in this patient cohort. The liver parenchyma has been considered to be structurally normal in CNS, but there is growing evidence of clinically silent but histologically significant fibrosis in CNS patients.Patients and methods: We included 13 patients in our retrospective study who underwent LT at our center. Patient survival, graft function, and long‐term complications were evaluated over a median follow‐up period of 10 years (range: 1–16 years). In addition, the prevalence of histologically relevant fibrosis was characterized.Results: The overall survival among our LT patients was 100%. The graft survival was only 61.5%. During the follow‐up period, 5 LT patients had to undergo retransplantation. More than 45% of our patients showed histological signs of fibrosis.Conclusion: LT remains the only definite therapeutic option for severe CNS but needs to be considered thoroughly regarding the clinical risk‐benefit‐ratio and impact on quality of life. Furthermore, hepatic parenchymal injury needs to be considered while evaluating future therapeutic options for CNS.

27 March 2021 in Transplant International
Verified
Journal Article
Open access
PDF file
JÖJulia Özen
Julia Özen
JBJan Beime
Jan Beime
FBFlorian Brinkert
Florian Brinkert
LFLutz Fischer
Lutz Fischer
UHUta Herden
Uta Herden
EGEnke Grabhorn
Enke Grabhorn
Background Pediatric liver transplantation (PLT) has very good results at experienced transplant centers. However, there is still an ongoing discussion about inferior outcomes, especially in young infants. The aim of this retrospective study was to evaluate outcomes of infants compared to older recipients in a single center over 20 years. Patients and methods We conducted a retrospective study of children who received liver transplants at our center between 1991 and 2011. Only patients without other limiting organ involvement were included and compared according to age. Results The inclusion criteria were fulfilled by 351 patients (173 versus 178). The most common indication in both groups was biliary atresia (82.1% versus 49.4%). The 1‐, 5‐ and 10‐year patient survivals were 93.8%/91.8%/91.1% and 93%/90.8%/90.1%, and the graft survivals were 90.4%/83.5%/79.6% and 89.4%/81.8%/77.5%, respectively. Complications such as postoperative bleeding, biliary complications or perfusion impairment occurred more often in infants. Leading indications for retransplantation (vascular complications/primary nonfunction) and leading causes of death (sepsis/multiorgan failure) were the same in both groups. Significant predictors for patient loss were decade of transplantation, retransplantation, postoperative bleeding and infections for infants. Predictors for graft loss were bowel perforation, arterial thrombosis and age > 12 months. Conclusion Children can have excellent results, independent of age at PLT.